Evidence map›Paper›PMID 40968101›Full record

Observational studyThoracic cancer2025

Patient-Reported Outcomes With First-Line Immunotherapy-Based Combination Treatment for Advanced Lung Cancer: A Prospective, Multicenter, Observational Study.

Rong Jia, Junyi Zou, Han Hu, Xiaoshan Wang, Yuzhu Zheng, Fan Yang, Yan Pang, Ke Wang, Yi Wang, Jianning Tang and 8 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rong JiaDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Junyi ZouDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0009-0008-8521-8602
Han HuSichuan Provincial People's Hospital East Sichuan Hospital and Dazhou First People's Hospital, Dazhou, China.
Xiaoshan WangCancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yuzhu ZhengDepartment of Medical Oncology, The Third People's Hospital of Chengdu, Chengdu, China.
Fan YangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0009-0003-9623-5081
Yan PangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Ke WangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yi WangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Jianning TangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Lingna KouDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yang LiuDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Jing DingDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Xin LiDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Wei DaiDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0003-1650-1590
Xing WeiDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0002-3035-5633
Qiuling ShiSchool of Public Health, Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0003-0660-3809
Jin ZhouDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Funding

2022CSCO key program Y-2021AST/zd-0119Construction of the whole process management and rehabilitation evaluation system of immunotherapy for advanced lung cancer based on patient-reported outcomes (PRO) 2025YFHZ0248Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer YC20210105
6 · The paper itself

Abstract

backgroundThis study aimed to characterize longitudinal trajectories of tumor burden and treatment-related symptoms following immune checkpoint inhibitor (ICI) therapy in patients with advanced lung cancer, based on electronic patient-reported outcomes (ePRO).

methodsUsing the MD Anderson Symptom Inventory-Lung Cancer module and an immune-related adverse event symptom item scale, we collected the ePRO data of patients undergoing first-line immunotherapy-based combination treatment for advanced unresectable primary lung cancer. Evaluating trajectories of primary symptoms and symptom differences between treatment groups using linear mixed-effects models.

resultsA total of 168 patients were included in the study. The top five symptoms with the highest severity before treatment were coughing, distress, shortness of breath, disturbed sleep, and pain. Coughing was gradually attenuated with ongoing treatment. Symptoms of distress, shortness of breath, disturbed sleep, and pain also showed an overall decreasing trend. The top five immunotherapy-related symptoms, with the highest severity, were early satiety, abdominal distension, night sweats, altered sense of taste, and bloated pain, which demonstrated a cyclical gradual increase throughout treatment. Compared to the ICIs + chemotherapy group, the ICIs + chemotherapy + VEGFR-TKIs group showed significantly lower burden in four of the top five immunotherapy-related symptoms, with the exception of night sweats, which demonstrated no significant difference.

conclusionsPatients with advanced lung cancer experienced reduced severity of lung cancer-related symptoms after receiving immunotherapy-based combination treatment, and immune-specific symptoms showed cyclical exacerbation with ongoing treatment. The addition of VEGFR-TKIs to ICIs + chemotherapy did not increase the associated toxicity burden.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyLung NeoplasmsPatient Reported Outcome MeasuresAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesImmune Checkpoint Inhibitorsimmunotherapylung cancerpatient‐reported outcomesymptom analysis

Identifiers

PMID40968101
PMCPMC12445973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.